The association between the concentration of different plasma lipoproteins and plasma factor VII (F VII) was analysed by isolating plasma very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) lipoproteins and assessing their in vitro interaction with F VII by immunoenzyme assay using peroxidase labelled anti-factor VII immunoglobulins to determine whether F VII coagulant activity is prognostic for cardiovascular mortality.
Meade et al showed that plasma coagulation factor VII (F VII) activity is as reliable a predictor for cardiovascular thrombosis as cholesterol and triglyceride plasma concentrations.' It is also well known that F VII activity is positively related to plasma lipid concentrations in healthy adults2 and in patients with cardiovascular disease. 3 It has previously been shown4 that F VII activity is increased in types IIb and IV hyperlipidaemic subjects, but a direct association between this activity and plasma lipoproteins has not yet been established. To our knowledge, correlation of lipoprotein concentrations with F VII have been studied only incidentally. Factor (F X) concentrations have been reported to be higher in type Ilb hyperlipidaemia and to have a positive correlation with plasma cholesterol and triglyceride concentrations. 45 The aim of this study was to investigate the possible direct interaction between plasma lipoproteins and coagulation factor VII.We developed two immunoenzyme assays to probe the adsorption offactors VII and X on lipoproteins.
Accepted for publication 7 April 1988 Material and methods Blood samples were obtained from five adults. Blood (nine volumes) was collected into polystyrene tubes with 0 13 M sodium citrate (one volume) and immediately centrifuged at 10 000 g for 10 minutes at room temperature. Plasma was kept at 4°C until isolation of lipoproteins was carried out.
Chylomicrons were isolated from plasma by flotation. Lipoproteins were isolated at a maximum of five hours after plasma collection by gradient ultracentrifugation according to the method ofChapman,6 and each fraction was collected separately. The lipoproteins were then dialysed against 01l M phosphate buffer (pH 7-4) over 12 hours at 4°C. To delipidate very low density lipoproteins (VLDL) and low density lipoproteins (LDL) we used the technique of ether delipidation, as described previously.7 IMMUNOENZYME PROCEDURES We used 96-well polystyrene microtitre plates for enzyme linked immunosorbent assay (ELISA) (Dynatech Laboratory, Paris). Prekonativ (Kabi Flow Laboratories, Paris) was used as factor VII and X 940
Association betweenfactors VII and X with triglycerides concentrate. Factors VII and X activities were 0 45 U/ mg and 1 15 U/mg, respectively (one U represents the amount contained in one millilitre of normal plasma).
Buffer and reagent used for immunoenzyme assay were as follows: phosphate buffered saline-albumin buffer, pH 7-6 (0-15 M NaCl, 0 07 M P04 HNa2, 0-0015 M P04 H2 K, 1 g bovine albumin in one litre of distilled water). In the experiments with Tween 20, 0 5 ml of this was added to one litre of buffer. Trisimidazole buffer was made up with imidazole (1 36 g/l), Tris (0 1 M), pH 7.3, 1 g bovine albumin in one litre of distilled water. This buffer was also made with and without calcium (M/80). Carbon/bicarbonate buffer (pH 9-6) was made up with sodium bicarbonate 8 g and sodium carbonate 14-6 g in one litre ofdistilled water.
Reagent for the determination of peroxidase activity comprised 40 mg of orthophenylene diamine (OPD) dissolved in 100 ml pH 5 buffer consisting of 005 M citric acid and 0-1 M Na2HPO4, to which were added 40 p1 of 30% hydrogen peroxide.8
Anti-F VII and anti-F X peroxidase-labelled immunoglobulins were obtained from Diagnostic Stago Laboratories, Asnieres, France. Anti-Apo Al, anti-Apo AII, and anti-Apo B immunoglobulins were obtained from antisera as described previously.9 AntiApo Al, anti-Apo AII, anti-Apo B, anti-Apo CIII, and anti-Apo E monoclonal antibodies were kindly given by Professor Fruchart, Service de Biochimie, Institut Pasteur de Lille, France. Phospholipase C from Bacillus Cereus was purchased from Sigma, St Louis, Missouri, USA.
DIRECT ASSAY (fig 1)
Ninety six-well polystyrene microplates (DynatechMicroelisa) were coated by adding 150 p1 of lipoprotein fractions to each well and incubating overnight at 37°C. The plates were washed four times with 0-15 M NaCl containing (or not) 005% Tween 20, using a Dynatech washer. Another incubation with bovine albumin (30 mg/ml in distilled water) was done in all wells for two hours at 37°C to avoid subsequent non-specific adsorption. Prekonativ was dissolved in Tris-imidazole buffer (2 mg/ml) with and without Tween 20, and 200 p1 was added to each well.
After two hours' incubation at 37°C the plates were washed four times with 0-15 M NaCl containing (or not) Tween 20. Two hundred p1 ofperoxidase-labelled anti-F VII or anti-F X Ig G in the PBS-albumin buffer was added. After two hours' incubation at 37°C the plates were washed four times and peroxidase-labelled IgG bound to the wells was determined by adding into each well 200 p1 orthophenylene diamine (OPD) solution: the colour development was stopped after exactly 240 seconds by adding 50 p1 of 2-5 N sulphuric acid. The absorbance was measured at 492 nm using an autoreader (Dynatech).
In another series of experiments a solution of phospholipase C (100 pg/ml final concentration in PBS buffer) was added to each well before F VII or F X concentrates and then the same method was applied. Each test in each of the five different plasmas was performed in triplicate and results were taken as the mean value (differences between the three determinations were always less than 5%). A procedure using polystyrene bound polyclonal and monoclonal antibodies against apolipoproteins as capture antibodies was used. Ninety six-well polystyrene microplates (Dynatech-Microelisa) were coated by adding to each well 150 p1 of each antibody dissolved in carbonate/bicarbonate buffer, pH 9-6 (50 pg/ml) and incubated overnight at 37°C. The plates were then washed four times with 0 15 M NaCl, and another incubation with bovine albumin (3% in PBS buffer) was done in all wells (200 p1/well) for two hours at 37°C to avoid future non-specific adsorption. Two hundred p1/well of several dilutions of a normal citrated plasma in PBS-albumin buffer were then added to all wells and another two hours' incubation at 37°C was carried out. After this the plates were washed four times with 015 M NaCl. Prekonativ dissolved in Tris-imidazole buffer (2 mg/ml) was added to each well. The experiment was then continued as described for the direct assay.
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For all the experiments negative controls were carried out with bovine albumin (3% in PBS buffer) coated wells.
Results
We first analysed the interaction of F VII with isolated lipoprotein fractions in a purified system. The results of these tests carried out with anti-F VII peroxidaselabelled immunoglobulin showed binding of F VII to chylomicrons, VLDL, and LDL. This binding was greater for VLDL than for LDL (fig 2) . HDL fractions bound minimal amounts of F VII.
The uncoated wells showed no binding (optical density less than 0 01).
To assess the type of interaction we analysed the effect of calcium and detergents. When F VII or X were added to lipoprotein coated wells in Trisimidazole buffers with or without calcium (M/80) no difference was found between experiments (optical density difference less than 5%). When Tween 20 was used in NaCI or in reagent buffers after coating no immunoperoxidase-labelled Ig bound to any of the lipoproteins.
To test the specificity of this association between triglyceride rich plasma lipoproteins and F VII, we performed the same experiments with F X. The binding of F X follows the same pattern as that of F VII (fig 3) . F X also binds preferentially to triglyceride rich lipoproteins. In an attempt to identify the molecules implicated in this interaction we investigated the effect of phospholipase C. It seemed to amplify the binding of F VII and X (figs 2 and 3).
Ether delipidation ofVLDL and LDL abolished the binding of F VII and greately decreased that of F X (fig 4) .
Finally, in indirect assays we tested the adsorption of F VII to plasma lipoproteins captured by polyclonal and monoclonal antibodies. Lipoproteins bound to anti-Apo B, anti-Apo CIII, and anti-Apo E monoclonal antibodies (table) This difference is also apparent in the experiments with phospholipase C. Phospholipase C action to 1/10 000, but these HDL lipoproteins were recogn-increases the fixation of F VII, in contrast to its action ised by coated antibodies as we were able to identify on procoagulant complexes.'4 The increased fixation them by peroxidase-labelled immunoglobulins to Apo might be due to the greater availability ofneutral lipids Al (results not shown).
after phospholipase action. The role of neutral lipids
Repeating the experiments with Tween 20 added in this form of adsorption is implicated not only by after lipoprotein capture (as for direct assays) showed their distribution among the lipoproteins but also by that no immunoperoxidase-labelled Ig was bound to the effect of ether treatment, which abolishes the any of the lipoproteins (optical density always less adsorption-probably because it removes neutral than 0001).
lipids. Association betweenfactors VII and X with triglycerides 944 de Sousa, Soria, Ayrault-Jarrier, Pastier, Bruckert, Amiral, Bereziat, Caen isolated lipoproteins (results not shown). These negative results do not exclude an interaction in vivo as the labile adsorption of coagulation factors can be successfully abolished by the ultracentrifugal procedure.
Additionally, there is some indirect evidence of in vivo interaction between F VII and triglycerides from clinical studies which show a positive correlation between F VII and plasma triglyceride concentration. The functional activity of F VII bound to immobilised triglyceride rich lipoproteins should be investigated to see if fixation affects activation of the molecule.
The capacity of VLDL and LDL atherogenic lipoproteins to bind F VII in a different way from procoagulant phospholipids may well be of potential importance. This could be reflected in epidemiological correlations between lipids, F VII, and cardiovascular thrombosis.
